A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight ...
A small percentage have had vision problems, but a direct causal link with the drugs has not been established.
News Medical on MSN2d
Vision loss risks in patients using popular GLP-1 medications raise concernsA small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.
A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...
Get Instant Summarized Text (Gist) Once-weekly semaglutide use in individuals with type 2 diabetes more than doubles the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION ...
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback